Thursday, October 18, 2012
Publication and contact
properties of protein therapeutics through peptide extensions that interact
with the Fc
fragment of IgG receptor transporter-a (FCGRT;
Peptide extensions that
promote the interaction of proteins with FCRN could improve the drug-like
properties of protein therapeutics. Some protein therapeutics are conjugated
to the Fc domain of IgG, which interacts with FCRN, to increase plasma
half-life, but the large size of the resulting fusion protein can interfere
with tissue penetration and biological activity. In a proof-of-principle
experiment, short peptide sequences that compete with IgG for binding to FCRN
were conjugated to the N-terminal and/or C-terminal ends of a fluorescent
protein. In cell culture, the peptide-based fusion proteins were internalized
and transcytosed across a cell monolayer, which is similar to what is seen
with IgG fusions. Next steps include testing peptide-modified protein
therapeutics in animal models.
Published online Oct. 18, 2012
Patent application filed;
available for licensing
Sockolosky, J.T. et al.
Proc. Natl. Acad. Sci. USA; Sept. 18, 2012;
Contact: Francis C. Szoka, University of California, San
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]